Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maintenance antidepressant continuation versus discontinuation to prevent depression relapse in primary care
2015-004210-26Phase 4Completed
- Sponsor
- PRIMENT Clinical Trials Unit
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of citalopram, sertraline, fluoxetine and mirtazapine in major depressive disorder (MDD) and recurrent depressive disorder (RDD) (2 arms), sponsored by PRIMENT Clinical Trials Unit. Primary endpoint: Relapse of depression. Started Apr 2017; status: completed.
02
Drugs
citalopramsertralinefluoxetinemirtazapine
03
Conditions
major depressive disorder (MDD)recurrent depressive disorder (RDD)
Beyond the preview
Go deeper on 2015-004210-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004210-26.